Certara will participate in 10 seminars and forums, launch the new version of its Phoenix PK/PD software platform, and support the National Organization for Rare Disorders during the show.
PRINCETON, NJ – Oct. 31, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that its Simcyp® and Pharsight® consultants will participate in 10 seminars and forums at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition being held from Nov. 2-6 at the San Diego Convention Center in San Diego, Calif.
Certara is also launching the latest version of its industry-leading Phoenix® software platform at the AAPS meeting. The Phoenix platform is used to analyze, manage, report and validate pre-clinical and clinical pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) data for model-based drug development.
“AAPS is an important, multi-disciplinary, international organization that is dedicated to improving public health. It clearly recognizes the vital contribution that PK/PD modeling is making to the drug development process,” said Certara CEO Edmundo Muniz, M.D., Ph.D. “We are proud to be able to make such a significant contribution to this meeting.”
Certara’s contributions to AAPS sessions are outlined below:
Nov. 4
- 9:00 – 11:00 a.m. – “A Gentle Touch on a Beating Heart: Early Discovery & Prediction of Cardiotoxicity and Its Covariates.” – Vice President and Lead Scientist, Research and Development, Christine Garnett
- 9:50 – 10:15 a.m. – “In Vitro to In Vivo Extrapolation of Cardiotoxicity Information; Considering Population Variability – Does It Even Matter?” – Principal Scientist, Modeling and Simulation, Sebastian Polak
- 10:55 – 11:10 a.m. – “The New Phoenix platform. Beyond WinNonlin®. Moving Your Research Forward.” – Senior Director of Deployment and Automation Services, Erin Guinan
- 2:00 – 4:00 p.m. – “Successful Drug Development with Novel Gut Absorption Models and Physiologically-based IVIVCs: Do U C What I C?” – Principal Scientist and Acting Deputy Head of Modeling & Simulation, David Turner
- 2:00 – 2:25 p.m. – “Conventional Versus Physiologically-Based (Pb)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with Pb-IVIVC.” – Senior Research Scientist, Modeling and Simulation, Nikunj Patel
Nov. 5
- 6:00 – 9:00 p.m. – Open Forum: “Contemporary Approaches for the Assessment of Organ-specific Toxicity: Critical Role of ADME Processes, Toxicokinetic Advances in Predictive Safety Assessment, and PK/PD Facilitation of and Impact on Drug Development.”
- 7:10 – 7:20 p.m. – “Bridging the Gap: In Vitro/In Vivo Extrapolations.” – Sebastian Polak
Nov. 6
- 8:30 – 11:00 a.m. – “Coming of Age? PBPK in Infants and Young Children.” – Vice President, Research & Development, Simcyp, Amin Rostami
- 8:30 – 9:00 a.m. – “PBPK in Pediatric Drug Development: Developing the Models, Refining the System Parameters.” – Principal Scientist and Deputy Head of Systems Pharmacology, Trevor Johnson
- 9:00 – 11:00 a.m. – “Inducing a Long-suppressed Debate: Implications, Appropriate Assessment and the Prediction of Induction & Suppression of Enzymes and Transporters.” – Principal Scientist, Translational Science in DMPK, Lisa Almond
Certara will also be exhibiting in booth #3537, where senior staff members will be available to take questions, provide Phoenix 1.4 demonstrations, and discuss the company’s expert consultancy services.
In addition, Certara will make a donation to the National Organization for Rare Disorders on behalf of everyone who visits its AAPS booth and posts their name on its Wall of Donations.
For more information about the AAPS meeting, please visit http://www.aaps.org/annualmeeting/.
Certara（サターラ）について
Certara is the leading global technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety.
お問合せ先
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
teresa.bradford@certara.com
報道機関の皆様：
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com
